Abstract
Background and Aims
Thyroid hormones regulate growth, development, differentiation and metabolism of virtually all tissues of vertebrates. The kidney and cardiovascular system are some of the most important targets of the thyroid hormones [1] . Kidney and thyroid function are interrelated through several mechanisms. Thus, thyroid hormones are necessary for the maintenance of electrolyte and water homeostasis (directly by affecting the glomerular /tubular kidney function and the structure of the kidney itself and indirectly by affecting the cardiovascular system and the renal blood flow). Meanwhile, the kidney is involved in the regulation of thyroid hormones metabolism. The kidney contributes to the iodine clearance primarily by glomerular filtration. Serum iodine concentrations are elevated in patients with chronic kidney disease (CKD) but not correlated with the degree of kidney failure [2, 3] . The excess of serum iodine has been linked to increased prevalence of goiter and hypothyroidism in patients with CKD [4, 5] .
Previous studies have shown that CKD patients have low triiodothyronine (T3), normal or reduced thyroxine (T4) levels, and consequently elevated thyroid-stimulating hormone (TSH) [6, 7] .
In [8] .
The aim of this study was to explore the prevalence of thyroid dysfunction in a cohort of patients with diabetes mellitus and CKD from Bucharest, Romania.
Material and Method
A total of 23 patients with diabetes mellitus and CKD in the pre-dialysis phase were recruited for this study. The term pre-dialysis has not been defined in guidelines. [9] . In this classification, preparation for renal replacement therapy (RRT) has been recommended in the stage characterized by a reduction of the estimated GFR to <30 ml/min. In our study, pre-dialysis care was defined as CKD with a possible need for RRT. All subjects were investigated with thyroid ultrasound and laboratory tests. Laboratory tests to determine thyroid function include: serum triiodothyronine (T3), free thyroxine (free T4), thyroid-stimulating hormone (TSH) and antithyroid peroxidase autoantibodies (ATPO). TSH, free T4 and T3 were measured by radioimmunoassay and ATPO by Enzyme-linked Immunosorbent Assay (ELISA) technique. Results were compared with the same measurements in 21 patients with diabetes mellitus but without CKD. The study protocol and informed consent were approved by the Institutional Ethics Committee. All subjects provided written informed consent before participating in this study.
Statistical analysis
Data are presented as mean±SD. Clinical characteristics were compared using the t Student Test. Pearson's moment-product correlation coefficients were calculated to evaluate correlations between variables. Significance was defined at the 0.05 level of confidence. All calculations were performed using the Statistical Package for Social Sciences Software (SPSS) version 15.
Results
The subjects were aged between 52 and 64 years (median age was 55±2 years in diabetic patients with CKD and 54±3 years in patients without CKD) and had an evolution of diabetes between 12 and 22 years. We observed a high prevalence of thyroid morphology abnormalities (diffuse or nodular goiter) in diabetic patients with CKD (12 patients -52.17%: 7 patients with diffuse goiter and 5 patients with nodular goiter). Thyroid ultrasound aspects of nodular and diffuse goiter are shown in Figures 1 and 2 . Five diabetic patients with CKD (23.80%) had subclinical hypothyroidism (subclinical hypothyroidism is defined as a clinical syndrome of hypothyroidism associated with raised serum TSH but free T4 in the normal range), 2 patients (8.69%) had overt hypothyroidism (overt hypothyroidism is defined as a clinical syndrome of hypothyroidism associated with elevated TSH and decreased serum levels of circulating thyroid hormone) and 5 patients had low T3 syndrome (23.80%). In the control group the prevalence of goiter was 19.04% (4 patients). Subclinical hypothyroidism was present in 2 patients (9.52%) while one patient (4.76%) was diagnosed with overt hypothyroidism. Statistically significant differences were recorded between diabetic patients with and without CKD for the prevalence of goiter (52.17% vs. 19.04%, p<0.05), subclinical hypothyroidism (23.80% vs. 9.52%, p<0.05), overt hypothyroidism (8.69% vs. 4.76%, p<0.05) and low T3 syndrome (23.80% vs. 0.00% p<0.05) as shown in Figure 3 . The incidence of autoimmune thyroid disease was similar in both groups. 
Discussions
Previous studies have shown that patients with CKD have mild reductions in thyroid function, but these abnormalities could represent a risk factor for cardiovascular disease and might be also involved in kidney disease progression [5, 6] .
The low T3 syndrome and subclinical hypothyroidism are the most frequently thyroid function disorders in patients with CKD. In our study the prevalence of low T3 syndrome and subclinical hypothyroidism was 23.80% in patients with CKD. The clinical importance of low T3 syndrome is controversial. A reduction in total T3, concentrations was associated with increased cardiovascular mortality in euthyroid CKD patients [10] while low T3 syndrome before renal transplantation was associated with decreased survival of the graft [11] . The lowT3 syndrome in CKD patients has been also correlated with higher levels of inflammation markers, endothelial dysfunction and cardiovascular mortality [12] [13] [14] .
Our findings add to data from other studies that report a high prevalence of low T3 syndrome and subclinical hypothyroidism in patients with CKD. Thus, Lim VS et al. reported that prevalences of low T3 were 80% in nonhaemodialysis patients and 43% in haemodialysis patients [15] [18] . Our data showed a high prevalence of thyroid morphology abnormalities (diffuse or nodular goiter) in diabetic patients with CKD which is concordant with data from a study conducted by Hegedüs L et al reporting that thyroid gland volume (ultrasonically determined) is increased in patients with CKD [19] .
All patients with overt hypothyroidism should be treated with thyroxine, and the dose should be adjusted to normalize the serum TSH concentration. The role of therapy in patients with subclinical hypothyroidism and low T3 syndrome is more controversial. In a recent issue of of Thyroid, Shin DL et al published an article entitled: " Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism". The authors evaluated 113 CKD patients with subclinical hypothyroidism treated with L-thyroxine. The treatment improves the GFR, suggesting that substitution therapy attenuates the decline of renal function [20] .
A limitation of our study is represented by the relatively small number of patients enrolled.
Future clinical and experimental studies should explore potential causal mechanisms linking low T3 syndrome, subclinical hypothyroidism and CKD.
Conclusions
We observed a high prevalence of thyroid morphology abnormalities and thyroid function disorders in diabetic patients with CKD. Low T3 syndrome and subclinical hypothyroidism are the most frequently thyroid function disorders in CKD diabetic subjects.
